Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28608372 | 0.76 | CPB1 (0.34) | THRATHRBF2PRSS1 | |
| SCHEMBL28594264 | 0.76 | CPB1 (0.34) | THRATHRBF2PRSS1 | |
| SCHEMBL28603572 | 0.76 | CPB1 (0.34) | THRATHRBF2PRSS1 | |
| SCHEMBL28586161 | 0.76 | CPB1 (0.34) | THRATHRBF2PRSS1 | |
| SCHEMBL21214210 | 0.75 | — | — | |
| SCHEMBL23484741 | 0.71 | SMYD3 (0.37) | THRATHRBSMYD3 | |
| SCHEMBL31269736 | 0.71 | SMYD3 (0.34) | SMYD3 | |
| SCHEMBL102383 | 0.71 | THRA (0.42) | THRATHRB | |
| SCHEMBL13152771 | 0.71 | THRA (0.42) | THRATHRB | |
| SCHEMBL13152808 | 0.71 | THRA (0.42) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688742-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024200768-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-10-03 | — | — | WO | disclosed |